<DOC>
	<DOCNO>NCT02540551</DOCNO>
	<brief_summary>Recently investigator show SN procedure perform injection tracer ovarian ligament feasible promising patient clinical early stage ovarian cancer ( OC ) . Injection radioactive tracer result identification SNs 21 patient . Before multicentre prospective trial initiate , still question answer , especially SN procedure still feasable patient OC injection tracer ovarian ligament , ovarian tumour already resect , either surgical procedure ( ovarian tumour resect frozen section malignancy result ) second surgical procedure complete staging procedure ( laparotomy laparoscopy ) .</brief_summary>
	<brief_title>Sentinel Node Detection Ovarian Cancer</brief_title>
	<detailed_description>Rationale : As cancer , ovarian cancer also spread regional lymph node . The concept sentinel lymph node surgery see whether cancer spread first lymph node sentinel node ( SN ) . If SN contain cancer , high likelihood cancer spread lymph node . This mean , least theoretically , radical lymphadenectomy could omit thus associate morbidity . The SN technique proven effective cancer breast cancer malignant melanoma . In gynaecological field show effective vulvar cancer . Recently investigator show SN procedure perform injection tracer ovarian ligament feasible promising patient clinical early stage ovarian cancer ( OC ) . Injection radioactive tracer result identification SNs 21 patient . Before multicentre prospective trial initiate , still question answer . Objectives : 1 . To determine whether SN procedure patient OC feasible injection tracer ovarian ligament , ovarian tumour already resect 1. surgical procedure ( ovarian tumour resect frozen section malignancy result ) 2. second surgical procedure complete staging procedure ( laparotomy laparoscopy ) , become actual previously resect apparently benign ovarian tumour appear malignant definite pathology . 2 . To determine blue colorization sentinel node injection blue dye relate time-interval injection retroperitoneal exploration ? 3 . To determine technique becomes accurate use mobile gamma-camera guidance surgical procedure . Study design : phase I feasibility study . Study population : following patient include : - Patients high suspicion ovarian malignancy median laparotomy frozen section analysis plan . - Patients previously adnexal mass remove appeared malignant , surgical staging procedure plan . Intervention ( applicable ) : Injection blue dye radioactive-colloid ligamentum ovarium proprium ligamentum infundibulo-pelvicum . This do side ( suspect ) malignancy . Main study parameter : Percentage patient feasible identify SN 's case malignant ovarian mass already resect . Nature extent burden risk associate participation , benefit group relatedness : case tracer inject adnexal mass still situ , surgery prolong maximum 20-25 minute due require incubation time injection blue dye radioactive isotope . A scintigram perform 24 hour surgery determine whether residual radioactive lymph node detect . The scintigram perform patient capable transport nuclear department . No extra blood sample take , extra visit , physical examination test necessary . There risk tumour dissemination inject tracer ovarian ligament . There 0.07 2.7 % risk allergic reaction blue dye . The dose radioactive isotope give give adverse side effect , either patient personnel present operate theatre .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patients high suspicion malignant ovarian tumour plan exploratory laparotomy . Only malignancy confirm frozen section , SNs remove prior proceed complete staging procedure . Patients ovarian malignant tumour already resect second surgical procedure plan complete staging procedure include lymph node . Mentally competent give inform consent . Previous vascular surgery aorta , caval vein , and/or iliac vessel . Previous lymphadenectomy lymph node sample iliac paraaortal region . History malignant lymphoma . History malignant tumour abdominal cavity . Previous allergic reaction blue dye . Pregnant lactating patient . An allergy human albumin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>